The future of biotech will likely involve products that patients are willing to pay for, focusing on conditions that significantly impact their quality of life.

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.

When evaluating biotech companies, the demand for their product is often clear, but the challenge lies in their ability to deliver on that promise.

I believe in focusing on problems that have a 10x positive or negative impact, especially in fintech where growth and compliance are critical.

When pitching to investors, it's crucial to speak their language, focusing on growth, traction, and market opportunity, especially when discussing products that address serious pain points.

A great product manager is relentless in validating impact and ensuring it is in place, often realizing that making current value more accessible can be more impactful than developing new features.

As a product manager, prioritize making an impact over seeking promotions; this mindset will guide your daily actions.

Prioritizing features in product development is essential to ensure that the most critical aspects are addressed first.

Drug design is complex, with numerous bottlenecks before reaching clinical trials, and we need to innovate in this space to improve the process.